山東新華製藥股份(00719.HK)與真實生物簽署戰略合作協議
格隆匯4月26日丨山東新華製藥股份(00719.HK)發佈公吿,2022年4月26日,公司與河南真實生物科技有限公司(以下簡稱“真實生物”)簽署《戰略合作協議》,真實生物同意新華製藥為其擁有的阿茲夫定等產品在中國及經雙方同意的其他國家的產品生產商和經銷商。
該合作協議主要內容為:基於真實生物致力於藥品的研發和註冊,並擁有阿茲夫定等產品的藥品註冊證書和/或專利權,以及相關有價值的和專有的信息和數據;新華製藥擁有cGMP的藥品生產能力,同意依照註冊文件中規定的相關要求為真實生物生產相關產品,滿足真實生物在中國及潛在的國際市場的註冊和銷售需求。真實生物同意新華製藥為其在中國及經雙方同意的其他國家的產品生產商和經銷商。
雙方同意後續將基於公平、合理、合規的原則,協商並簽署單獨的《委託生產協議》和《技術質量協議》。自本協議生效日期開始起算,本協議在該日期後的10個日曆年內持續有效。除非由雙方協商終止,或協議一方或雙方根據本協議約定提前終止。本協議的簽署有利於公司現代醫藥國際合作中心產能發揮,對公司2022年度及未來財務狀況和經營成果的影響需視具體項目的推進和實施情況而定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.